113.63
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$113.03
Aprire:
$112.95
Volume 24 ore:
1.15M
Relative Volume:
0.15
Capitalizzazione di mercato:
$141.41B
Reddito:
$28.73B
Utile/perdita netta:
$5.97B
Rapporto P/E:
23.92
EPS:
4.75
Flusso di cassa netto:
$9.84B
1 W Prestazione:
+3.32%
1M Prestazione:
+2.85%
6M Prestazione:
+19.08%
1 anno Prestazione:
+46.44%
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
GILD
Gilead Sciences Inc
|
113.68 | 144.54B | 28.73B | 5.97B | 9.84B | 4.75 |
![]()
LLY
Lilly Eli Co
|
772.41 | 729.58B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
168.06 | 405.32B | 90.63B | 22.66B | 16.40B | 9.35 |
![]()
ABBV
Abbvie Inc
|
190.88 | 336.11B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
117.58 | 227.85B | 55.19B | 13.65B | 16.81B | 6.86 |
![]()
MRK
Merck Co Inc
|
80.28 | 212.71B | 63.92B | 17.43B | 17.04B | 6.87 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-25 | Aggiornamento | Needham | Hold → Buy |
2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
2025-03-04 | Reiterato | Oppenheimer | Outperform |
2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | Ripresa | BofA Securities | Buy |
2024-11-15 | Iniziato | Wolfe Research | Outperform |
2024-11-14 | Iniziato | Citigroup | Buy |
2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2024-10-17 | Iniziato | Bernstein | Outperform |
2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2024-05-01 | Reiterato | Maxim Group | Buy |
2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
2024-02-22 | Downgrade | Truist | Buy → Hold |
2023-11-09 | Iniziato | Deutsche Bank | Hold |
2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
2023-09-06 | Iniziato | HSBC Securities | Reduce |
2023-07-24 | Reiterato | Barclays | Equal Weight |
2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2023-04-28 | Ripresa | Piper Sandler | Overweight |
2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2022-12-13 | Ripresa | BofA Securities | Neutral |
2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
2022-10-28 | Reiterato | Cowen | Outperform |
2022-10-28 | Reiterato | JP Morgan | Overweight |
2022-10-28 | Reiterato | Jefferies | Buy |
2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
2022-10-28 | Aggiornamento | Truist | Hold → Buy |
2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
2022-02-02 | Reiterato | BofA Securities | Neutral |
2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
2022-02-02 | Reiterato | Truist | Hold |
2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
2022-01-28 | Aggiornamento | Argus | Hold → Buy |
2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
2021-12-06 | Iniziato | Goldman | Neutral |
2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2021-11-19 | Ripresa | Piper Sandler | Neutral |
2021-10-20 | Ripresa | Cowen | Outperform |
2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
2020-10-28 | Iniziato | UBS | Neutral |
2020-09-30 | Ripresa | Jefferies | Buy |
2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
2020-07-31 | Reiterato | Credit Suisse | Neutral |
2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
2020-07-31 | Reiterato | Piper Sandler | Overweight |
2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
2020-07-31 | Reiterato | SunTrust | Hold |
2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
2020-05-01 | Downgrade | SunTrust | Hold → Sell |
2020-04-27 | Downgrade | UBS | Buy → Neutral |
2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Integrase Inhibitors Market Growth and Future Scope 2025-2032 | - openPR.com
Why Gilead Sciences Stock Slipped Today - Yahoo Finance
Gilead down as analysts see RFK Jr. preventative task force action negatively - Seeking Alpha
Gilead Sciences stock falls amid reports of preventive health panel dismissal - Investing.com
BMO Capital Has An Important Take On Gilead Sciences, Retail’s Keeping The Optimism Alive - Stocktwits
Is Gilead Sciences Inc. stock overvalued or undervaluedConsistent double returns - jammulinksnews.com
Gilead Sciences Earns Membership In 95-Plus Composite Rating Club - Investor's Business Daily
Citi Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey
TD Cowen Remains Bullish on Gilead Sciences (GILD) - Yahoo Finance
What is Gilead Sciences Inc. company’s growth strategyFree Predictions - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet? - simplywall.st
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live
Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance
Why Gilead Sciences Stock Just Popped - Yahoo Finance
EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three - insights.citeline.com
Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales - Benzinga
EU regulator backs Gilead's twice-yearly injection for HIV prevention - Reuters
Gilead upgraded to Buy at Needham on new HIV drug - MSN
Gilead Sciences (GILD) Gains Upgrade Amid Promising HIV Drug Outlook - GuruFocus
Gilead stock upgraded at Needham on new HIV drug (GILD:NASDAQ) - Seeking Alpha
What analysts say about Gilead Sciences Inc. stockFree Stock Market Beginners Guide - PrintWeekIndia
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
Analyst recommendations: Thermo Fisher Scientific, Intel, Honeywell International, Union Pacific, Gilead Sciences... - MarketScreener
This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
EU regulator backs Gilead’s twice-yearly injection for HIV prevention - PharmaLive
Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet - Stocktwits
Gilead wins EU backing for twice-yearly HIV PrEP therapy - Seeking Alpha
Gilead Sciences’ Yeztugo: A Promising Growth Driver in the HIV PrEP Market with Undervalued Potential - TipRanks
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention - BioSpace
Gilead receives positive EU opinion for twice-yearly HIV prevention drug - StreetInsider
Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention - Investing.com
Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention By Investing.com - Investing.com Nigeria
Gilead Sciences and the Breakthrough Approval of Lenacapavir for HIV PrEP: A New Era in Global Health and Market Leadership - AInvest
Gilead Receives Positive Chmp Opinions Under Accelerated Review From European Medicines Agency For Twice-Yearly Lenacapavir For HIV Prevention - vih.org
Is Gilead Sciences Inc. a good long term investmentMarket-leading profit generation - PrintWeekIndia
What drives Gilead Sciences Inc. stock priceAccelerated wealth expansion - PrintWeekIndia
Is Gilead Sciences Inc. stock a growth or value playTremendous gains - jammulinksnews.com
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - BioSpace
Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications - TipRanks
Gilead Sciences Advances HIV Prevention with New Clinical Study - TipRanks
Looking Back to the Future: Gilead’s Long-Standing Commitment To Help End the HIV Epidemic - CSRwire
Attorney General Jeff Jackson Secures Over $200 Million from Gilead Sciences for Paying Kickbacks to Doctors - NCDOJ (.gov)
AG Jackson announces major settlement with Gilead Sciences over kickbacks - WPDE
Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know - TradingView
Bridging the Gap: Gilead’s Work to Help End the HIV Epidemic - The Hollywood Reporter
Looking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic - ACCESS Newswire
What to Expect From Gilead Sciences’ Q2 2025 Earnings Report - MSN
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Lobbying Update: $1,700,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gilead Sciences Inc Azioni (GILD) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Mercier Johanna | Chief Commercial Officer |
Jul 15 '25 |
Sale |
111.03 |
3,000 |
333,090 |
117,168 |
Dickinson Andrew D | Chief Financial Officer |
Jul 15 '25 |
Sale |
111.03 |
2,500 |
277,575 |
162,610 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):